Statins and anti-inflammatory therapies for subarachnoid hemorrhage

Current Treatment Options in Neurology

Volumn 14, Issue 2, 2012, Pages 164-174

  Dhar, Rajat ^a   Diringer, Michael ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral vasospasm; Delayed cerebral ischemia; Edaravone; Endothelin antagonists; HMG CoA reductase inhibitors; Intracranial aneurysm; Pravastatin; Simvastatin; Statins; Subarachnoid hemorrhage; Tirilazad; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; CLAZOSENTAN; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; DILTIAZEM; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; ERYTHROPOIETIN; FIBRIC ACID DERIVATIVE; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; METHYLPREDNISOLONE; NICOTINIC ACID; NIMODIPINE; NITRIC OXIDE; NORPHENAZONE; PLACEBO; PRAVASTATIN; PROTEINASE INHIBITOR; SIMVASTATIN; TIRILAZAD; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

ANEMIA; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; BRAIN VASOSPASM; CLINICAL TRIAL (TOPIC); CONVENTIONAL ANGIOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG COST; DRUG FATALITY; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPOTENSION; LIFESTYLE MODIFICATION; LIVER FAILURE; LUNG EDEMA; META ANALYSIS (TOPIC); MYALGIA; MYOPATHY; NEUROPROTECTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; SIDE EFFECT; SPREADING CORTICAL DEPRESSION; SUBARACHNOID HEMORRHAGE; SYSTEMATIC REVIEW (TOPIC);

EID: 84861094284     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0163-z     Document Type: Article

References (76)

1. Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebocontrolled phase 2 dose-finding trial. Stroke. 2008;39(11):3015-21.
2. Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(8):2315-21. (Pubitemid 47457575)
3. Hijdra A, van Gijn J, Nagelkerke NJ, et al. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 1988;19(10):1250-6.
4. Pluta RM, Hansen-Schwartz J, Dreier J, et al. Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought. Neurol Res. 2009;31(2):151-8.
5. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by vasospasm-dependent and -independent effects. Stroke. 2011;42(4):924-9.
6. Provencio JJ, Vora N. Subarachnoid hemorrhage and inflammation: bench to bedside and back. Semin Neurol. 2005;25(4):435-44.
7. Chaichana KL, Pradilla G, Huang J, Tamargo RJ. Role of inflammation (leukocyte-endothelial cell interactions) in vasospasm after subarachnoid hemorrhage. World Neurosurg. 2010;73(1):22-41. This thorough review article summarizes the experimental and clinical evidence for inflammatory mechanisms underlying vasospasm.
8. Gruber A, Rossler K, Graninger W, et al. Ventricular cerebrospinal fluid and serum concentrations of sTNFR-I, IL-1ra, and IL-6 after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2000;12(4):297-306.
9. Fassbender K, Hodapp B, Rossol S, et al. Inflammatory cytokines in subarachnoid haemorrhage: association with abnormal blood flow velocities in basal cerebral arteries. J Neurol Neurosurg Psychiatry. 2001;70(4):534-7. (Pubitemid 32269696)
10. Schoch B, Regel JP, Wichert M, et al. Analysis of intrathecal interleukin-6 as a potential predictive factor for vasospasm in subarachnoid hemorrhage. Neurosurgery. 2007;60(5):828-36.
11. Gallia GL, Tamargo RJ. Leukocyte-endothelial cell interactions in chronic vasospasm after subarachnoid hemorrhage. Neurol Res. 2006;28(7):750-8. (Pubitemid 44656101)
12. Kubo Y, Ogasawara K, Kakino S, et al. Serum inflammatory adhesion molecules and high-sensitivity C-reactive protein correlates with delayed ischemic neurologic deficits after subarachnoid hemorrhage. Surg Neurol. 2008;69(6):592-6. (Pubitemid 351671852)
13. Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005;105(1):23-56. (Pubitemid 40044766)
14. Clark JF, Sharp FR. Bilirubin oxidation products (BOXes) and their role in cerebral vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006;26(10):1223-33. (Pubitemid 44435238)
15. Ryba M, Jarzabek-Chorzelska M, Chorzelski T, Pastuszko M. Is vascular angiopathy following intracranial aneurysm rupture immunologically mediated? Acta Neurochir (Wien). 1992;117(1-2):34-7.
16. Khurana VG, Sohni YR, Mangrum WI, et al. Endothelial nitric oxide synthase gene polymorphisms predict susceptibility to aneurysmal subarachnoid hemorrhage and cerebral vasospasm. J Cereb Blood Flow Metab. 2004;24(3):291-7. (Pubitemid 38314585)
17. Bavbek M, Polin R, Kwan AL, et al. Monoclonal antibodies against ICAM-1 and CD18 attenuate cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits. Stroke. 1998;29(9):1930-5. (Pubitemid 28399993)
18. Clatterbuck RE, Gailloud P, Ogata L, et al. Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg. 2003;99(2):376-82. (Pubitemid 36900133)
19. Yoshimoto Y, Tanaka Y, Hoya K. Acute systemic inflammatory response syndrome in subarachnoid hemorrhage. Stroke. 2001;32(9):1989-93. (Pubitemid 32868085)
20. Rothoerl RD, Axmann C, Pina AL, et al. Possible role of the C-reactive protein and white blood cell count in the pathogenesis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2006;18(1):68-72. (Pubitemid 44491162)
21. Dhar R, Diringer MN. The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage. Neurocrit Care. 2008;8(3):404-12.
22. Anderson CS, Feigin V, Bennett D, et al. Active and passive smoking and the risk of subarachnoid hemorrhage: an international population-based casecontrol study. Stroke. 2004;35(3):633-7. (Pubitemid 38280832)
23. Juvela S, Porras M, Poussa K. Natural history of unruptured intracranial aneurysms: probability of and risk factors for aneurysm rupture. J Neurosurg. 2008;108(5):1052-60. (Pubitemid 351656862)
24. Lasner TM, Weil RJ, Riina HA, et al. Cigarette smokinginduced increase in the risk of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1997;87(3):381-4. (Pubitemid 27362569)
25. Weir BK, Kongable GL, Kassell NF, et al. Cigarette smoking as a cause of aneurysmal subarachnoid hemorrhage and risk for vasospasm: a report of the Cooperative Aneurysm Study. J Neurosurg. 1998;89(3):405-11. (Pubitemid 28405254)
26. Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2000;92(3):390-400. (Pubitemid 30112378)
27. Krishnamurthy S, Kelleher JP, Lehman EB, Cockroft KM. Effects of tobacco dose and length of exposure on delayed neurological deterioration and overall clinical outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2007;61(3):475-80. (Pubitemid 47442610)
28. Gerzanich V, Zhang F, West GA, Simard JM. Chronic nicotine alters NO signaling of Ca (2+) channels in cerebral arterioles. Circ Res. 2001;88(3):359-65. (Pubitemid 32173762)
29. Seder DB, Schmidt JM, Badjatia N, et al. Transdermal nicotine replacement therapy in cigarette smokers with acute subarachnoid hemorrhage. Neurocrit Care. 2011;14(1):77-83.
30. Al Tamimi YZ, Orsi NM, Quinn AC, et al. A review of delayed ischemic neurologic deficit following aneurysmal subarachnoid hemorrhage: historical overview, current treatment, and pathophysiology. World Neurosurg. 2010;73(6):654-67. An excellent and concise but comprehensive overview of the concept of delayed cerebral ischemia (DCI) after subarachnoid hemorrhage. This article reviews multiple theories for DCI (including inflammatory mechanisms), summarizes a multitude of relevant studies, and discusses management options.
31. Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007; (3): CD000277.
32. Sehba FA, Pluta RM, Zhang JH. Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury. Mol Neurobiol. 2011;43(1):27-40.
33. Feigin VL, Anderson N, Rinkel GJ, et al. Corticosteroids for aneurysmal subarachnoid haemorrhage and primary intracerebral haemorrhage. Cochrane Database Syst Rev. 2005; (3): CD004583.
34. Hashi K, Takakura K, Sano K, et al. Intravenous hydrocortisone in large doses in the treatment of delayed ischemic neurological deficits following subarachnoid hemorrhage-results of a multi-center controlled double-blind clinical study. No To Shinkei. 1988;40(4):373-82.
35. Katayama Y, Haraoka J, Hirabayashi H, et al. A randomized controlled trial of hydrocortisone against hyponatremia in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38(8):2373-5. (Pubitemid 47457586)
36. Chyatte D, Fode NC, Nichols DA, Sundt Jr TM. Preliminary report: effects of high dose methylprednisolone on delayed cerebral ischemia in patients at high risk for vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1987;21(2):157-60. (Pubitemid 17131115)
37. Gomis P, Graftieaux JP, Sercombe R, et al. Randomized, double-blind, placebo-controlled, pilot trial of highdosemethylprednisolone in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2010;112(3):681-8.
38. Hall ED. Efficacy and mechanisms of action of the cytoprotective lipid peroxidation inhibitor tirilazad mesylate in subarachnoid haemorrhage. Eur J Anaesthesiol. 1996;13(3):279-89. (Pubitemid 26158487)
39. Zhang S, Wang L, Liu M, Wu B. Tirilazad for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2010; (2): CD006778.
40. Munakata A, Ohkuma H, Nakano T, et al. Effect of a free radical scavenger, edaravone, in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurosurgery. 2009;64(3):423-8.
41. van den Bergh WM, Algra A, Dorhout Mees SM, et al. Randomized controlled trial of acetylsalicylic acid in aneurysmal subarachnoid hemorrhage: the MASH Study. Stroke. 2006;37(9):2326-30. (Pubitemid 44337178)
42. Chyatte D, Rusch N, Sundt Jr TM. Prevention of chronic experimental cerebral vasospasm with ibuprofen and high-dose methylprednisolone. J Neurosurg. 1983;59(6):925-32. (Pubitemid 14205877)
43. Pradilla G, Thai QA, Legnani FG, et al. Local delivery of ibuprofen via controlled-release polymers prevents angiographic vasospasm in a monkey model of subarachnoid hemorrhage. Neurosurgery. 2005;57(1 Suppl):184-90.
44. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97(12):1129-35. (Pubitemid 28152885)
45. McGirt MJ, Lynch JR, Parra A, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke. 2002;33(12):2950-6. (Pubitemid 35462871)
46. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol Sci. 2002;23(10):482-6. (Pubitemid 35279610)
47. McGirt MJ, Pradilla G, Legnani FG, et al. Systemic administration of simvastatin after the onset of experimental subarachnoid hemorrhage attenuates cerebral vasospasm. Neurosurgery. 2006;58(5):945-51.
48. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154(1):87-96. (Pubitemid 32008567)
49. Cheng G, Wei L, Zhi-Dan S, et al. Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci. 2009;10:7.
50. Lynch JR, Wang H, McGirt MJ, et al. Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke. 2005;36(9):2024-6. (Pubitemid 41266547)
51. Tseng MY, Czosnyka M, Richards H, et al. Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke. 2005;36(8):1627-32. (Pubitemid 41098752)
52. Chou SH, Smith EE, Badjatia N, et al. A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage. Stroke. 2008;39(10):2891-3.
53. Vergouwen MD, Meijers JC, Geskus RB, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebocontrolled randomized trial. J Cereb Blood Flow Metab. 2009;29(8):1444-53.
54. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke. 2010;41(1):e47-52. A well-conducted meta-analysis of the published clinical trials of statins in SAH.
55. Tseng MY. Participants in the International Multidisciplinary Consensus Conference on the Critical Care Management of Subarachnoid Hemorrhage. Summary of evidence on immediate statins therapy following aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15(2):298-301.
56. Bederson JB, Connolly Jr ES, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40(3):994-1025.
57. Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12, 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658-69.
58. Singhal AB, Topcuoglu MA, Dorer DJ, et al. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology. 2005;64(6):1008-13. (Pubitemid 40388453)
59. Risselada R, Straatman H, van Kooten F, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke. 2009;40(8):2887-92.
60. Seifert V, Loffler BM, Zimmermann M, et al. Endothelin concentrations in patients with aneurysmal subarachnoid hemorrhage. Correlation with cerebral vasospasm, delayed ischemic neurological deficits, and volume of hematoma. J Neurosurg. 1995;82(1):55-62.
61. Kastner S, Oertel MF, Scharbrodt W, et al. Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir (Wien). 2005;147(12):1271-9. (Pubitemid 41674372)
62. Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke. 2000;31(12):2971-5.
63. Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618-25.
64. Macdonald RL, Higashida RT, Keller E, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care. 2010;13(3):416-24.
65. Santhanam AV, Smith LA, Akiyama M, et al. Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 2005;36(12):2731-7.
66. Jerndal M, Forsberg K, Sena ES, et al. A systematic review and meta-analysis of erythropoietin in experimental stroke. J Cereb Blood Flow Metab. 2010;30(5):961-8.
67. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647-56.
68. Tseng MY, Hutchinson PJ, Richards HK, et al. Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. J Neurosurg. 2009.
69. Hoh BL, Ogilvy CS. Endovascular treatment of cerebral vasospasm: transluminal balloon angioplasty, intra-arterial papaverine, and intra-arterial nicardipine. Neurosurg Clin N Am. 2005;16(3):501-16. vi. (Pubitemid 41766378)
70. Rosenwasser RH, Armonda RA, Thomas JE, et al. Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurgery. 1999;44(5):975-9.
71. Zwienenberg-Lee M, Hartman J, Rudisill N, et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke. 2008;39(6):1759-65.
72. McAuliffe W, Townsend M, Eskridge JM, et al. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. J Neurosurg. 1995;83(3):430-4.
73. Carhuapoma JR, Qureshi AI, Tamargo RJ, et al. Intraarterial papaverine-induced seizures: case report and review of the literature. Surg Neurol. 2001;56(3):159-63. (Pubitemid 32946846)
74. Clyde BL, Firlik AD, Kaufmann AM, et al. Paradoxical aggravation of vasospasm with papaverine infusion following aneurysmal subarachnoid hemorrhage. Case report J Neurosurg. 1996;84(4):690-5.
75. Dreier JP, Major S, Manning A, et al. Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage. Brain. 2009;132(Pt 7):1866-81.
76. Sabri M, Macdonald RL. Statins: a potential therapeutic addition to treatment for aneurysmal subarachnoid hemorrhage? World Neurosurg. 2010;73(6):646-53. An excellent summary of the history, rationale, pharmacology, and both experimental and clinical evidence for the use of statins in SAH.